In this phase 2 clinical trial, a combination of everolimus plus bevacizumab was looked at in 37 patients with papillary renal cell carcinoma (RCC). The study showed that the combination was effective and delayed progression of the disease (progression-free survival) on average for 13.7 months. There was a response rate of 35%, and overall survival of 33.9 months.

Side effects were similar to previous studies with everolimus plus bevacizumab.

In summary, this study confirms the effectiveness of everolimus plus bevacizumab in metastatic papillary RCC, supporting this treatment as a standard option for this patient population.

Read more in Practice Update here